6ws6

<table><tr><td colspan='2'>[[6ws6]] is a 6 chain structure with sequence from [http://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6WS6 OCA]. For a <b>guided tour on the structure components</b> use [http://proteopedia.org/fgij/fg.htm?mol=6WS6 FirstGlance]. <br>

</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=JEF:O-(O-(2-AMINOPROPYL)-O-(2-METHOXYETHYL)POLYPROPYLENE+GLYCOL+500)'>JEF</scene></td></tr>

<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://proteopedia.org/fgij/fg.htm?mol=6ws6 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6ws6 OCA], [http://pdbe.org/6ws6 PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=6ws6 RCSB], [http://www.ebi.ac.uk/pdbsum/6ws6 PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=6ws6 ProSAT]</span></td></tr>

<div style="background-color:#fffaf0;">

== Publication Abstract from PubMed ==

SARS-CoV-2 is a newly emerged coronavirus responsible for the current COVID-19 pandemic that has resulted in more than one million infections and 73,000 deaths (1,2) . Vaccine and therapeutic discovery efforts are paramount to curb the pandemic spread of this zoonotic virus. The SARS-CoV-2 spike (S) glycoprotein promotes entry into host cells and is the main target of neutralizing antibodies. Here we describe multiple monoclonal antibodies targeting SARS-CoV-2 S identified from memory B cells of a SARS survivor infected in 2003. One antibody, named S309, potently neutralizes SARS-CoV-2 and SARS-CoV pseudoviruses as well as authentic SARS-CoV-2 by engaging the S receptor-binding domain. Using cryo-electron microscopy and binding assays, we show that S309 recognizes a glycan-containing epitope that is conserved within the sarbecovirus subgenus, without competing with receptor attachment. Antibody cocktails including S309 along with other antibodies identified here further enhanced SARS-CoV-2 neutralization and may limit the emergence of neutralization-escape mutants. These results pave the way for using S309 and S309-containing antibody cocktails for prophylaxis in individuals at high risk of exposure or as a post-exposure therapy to limit or treat severe disease.

 

== References ==

[[Category: Human]]

[[Category: Beltramello, M]]

[[Category: Bianchi, S]]

[[Category: Cameroni, E]]

[[Category: Case, J B]]

[[Category: Chen, R E]]

[[Category: Corti, D]]

[[Category: Culap, K]]

[[Category: Diamond, M S]]

[[Category: Fink, K]]

[[Category: Guarino, B]]

[[Category: Havenar-Daughton, C]]

[[Category: Jaconi, S]]

[[Category: Lanzavecchia, A]]

[[Category: Marco, A D]]

[[Category: Park, Y J]]

[[Category: Peter, A]]

[[Category: Pinto, D]]

[[Category: Structural genomic]]

[[Category: Snell, G]]

[[Category: Spreafico, R]]

[[Category: Telenti, A]]

[[Category: Tortorici, M A]]

[[Category: Veesler, D]]

[[Category: Virgin, H W]]

[[Category: Walls, A C]]

[[Category: Zatta, F]]

[[Category: Ssgcid]]